News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

PDF 224 KB

 

Berlin (Germany) and Germantown, MD (U.S.A.), April 18, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, will present data from a validation study with a proprietary panel of blood-based DNA methylation biomarkers for the detection of lung cancer at the Annual Meeting 2016 of the American Association for Cancer Research (AACR) in New Orleans, Louisiana.

Epigenomics´ clinical research has received funding under the European Union Framework Program for Research and Innovation (Horizon 2020*) and is part of the ongoing development of the company’s novel, blood-based lung cancer test Epi proLung®. Liquid biopsy tests such as Epigenomics’ Epi proColon® and Epi proLung® tests have the potential to radically improve cancer diagnosis in the relevant patient populations.

The poster titled “Classification of patients with lung cancer and benign lung disease via assessment of DNA methylation of SHOX2 and PTGER4 in plasma” will be presented by

Dr. Gunter Weiss, Epigenomics’ Vice President Product Development, today, Monday, April 18, 2016, in a poster session.

Presentation details:

Abstract No: 2260
Title: Biomarkers for Lung Cancer
Authors: A. Schlegel, O. Hasinger, S. Esche, M. Martini, T. König, G. Weiss
Time: Monday, April 18, 2016, 1.00 pm – 5.00 pm
Location: Convention Center, Halls G-J, Poster Section 22
Session Category: Clinical Research

 

About lung cancer

According to the World Health Organization, lung cancer is the leading cause of cancer death worldwide. The vast majority of cases of lung cancer are due to long-term exposure to tobacco smoke. Early detection and treatment of lung cancer can save lives: Survival rates for patients with lung cancer fall as the stage at diagnosis becomes more advanced.

About Epigenomics

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The Company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics’ lead product, Epi proColon®, is a blood-based screening test for the early detection of colorectal cancer. Epi proColon® has recently received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in Europe, China and selected other countries. For more information, visit www.epigenomics.com.

*This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 672680.

 

Contact Epigenomics AG
Peter Vogt
Vice President
Corporate Communications & Investor Relations
Epigenomics AG
Tel +49 (0) 30 24345 368
ir@epigenomics.com

www.epigenomics.com

For U.S. press inquiries:
Deanne Eagle
Planet Communications
Tel: (917) 837-5866
deanne@planetcommunications.nyc

For European media inquiries:
Caroline Bergmann
MC Services AG
Tel.: +49 (0) 211 529 252 20
caroline.bergmann@mc-services.eu

 

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.